A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
A phase 3 trial of Golidocitinib run by Dizal Pharmaceuticals, now recruiting.
Overview
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) is a phase 3 interventional study registered as NCT07234162 by Dizal Pharmaceuticals, with 218 participants planned, started 2024-05-13. Conditions listed: Peripheral T-cell Lymphoma. No results are recorded here; the registry entry is the source.
Setting
A Phase 3, Open-Label, Randomized, Multinational Study to Investigate the Anti-tumor Efficacy of Golidocitinib Versus Investigator's Choice in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma
Phase
Phase 3
Sponsor
Dizal Pharmaceuticals
Registry
Enrolled
218